|
Polatuzumab Clinical Trials
4 actively recruiting trials across 3 locations
Also known as: Polatuzumab Vedotin, Polatuzumab vedotin, DCDS4501S, RG7596, Polivy, RO5541077
Pipeline
Phase 1: 1Phase 2: 3
Top Sponsors
- National Cancer Institute (NCI)1
- Memorial Sloan Kettering Cancer Center1
- Lazaros Lekakis1
- Jennifer Crombie, MD1
Indications
- Cancer4
- Lymphoma2
- Aggressive Non-Hodgkin Lymphoma1
- Lymphoma, Large B-Cell, Diffuse1
- Burkitt Lymphoma1
Miami, Florida2 trials
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
University of Miami Sylvester Cancer Center
Phase 2
Bethesda, Maryland1 trial
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Institutes of Health Clinical Center
Phase 1
Basking Ridge, New Jersey1 trial
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.